In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dean Rudge

Deputy Editor

London, UK

Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries since joining Generics Bulletin in 2013. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.

Latest From Dean Rudge

Krka Enjoys 9% Pharma Sales Growth At The Half-Way Stage

Krka insisted that its margins were “stable and high,” as the Slovenian firm reported another solid quarter.

Sales & Earnings Strategy

J&J Confirms EU Stelara Biosimilars Are Imminent

One of the largest biologic opportunities for inflammatory bowel disorders, Johnson & Johnson’s Stelara, will open up to biosimilar competition in a matter of days, the originator has confirmed.

Biosimilars Commercial

Xbrane Inching Closer To Cimzia Biosimilar Trials With Batch Production

Sweden’s Xbrane Biopharma has delivered updates for two of its more long-term projects, including a proposed biosimilar to Bristol Myers Squibb’s Opdivo for which it is actively seeking a partner.

Biosimilars Manufacturing

Zydus’s ‘Transparency Failure’ Leads To Block On Indian Perjeta Biosimilar

The principles of fairness in procedural conduct, especially in commercial disputes, is crucial,” Delhi’s High Court told Zydus Lifesciences as it agreed to temporarily block the sale of the firm’s recently launched biosimilar to Roche’s Perjeta.

Legal Issues Biosimilars

Cipla’s Verma Succeeds Kabi US Veteran Ducker As CEO

Guided by the firm’s ‘Vision 2026’ strategy, Fresenius Kabi has tapped Cipla executive Arunesh Verma to lead Fresenius Kabi USA, as former head John Ducker retires after 35 years.

Executive Changes Leadership

AEON Aims For Biosimilar Pathway For Lead Candidate In Cervical Dystonia

California-based clinical-stage firm AEON Biopharma has announced a strategic redirection for its lead product candidate – using the 351(k) biosimilar pathway, with the world-renowned Botox as the reference product.

Biosimilars Drug Review
See All